Study Finds Experimental Drug Prolongs the Survival of Glioblastoma Patients
A recent study whose findings appeared in the Nature Communications journal has shown that a new experimental drug can increase the survival time of patients who have been diagnosed with glioblastoma. This brain cancer is the most prevalent brain cancer in adults. The experimental drug, dubbed 186RNL (Rhenium Obisbemeda), was developed at UT Health San Diego. The trial established that this drug candidate, at the very least, doubled the progression-free and survival duration of study participants in comparison to the known progression-free or survival rates of patients afflicted by this brain tumor. It also didn’t have any side effects that…